SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is trending due to a massive volume spike and price surge, triggering multiple trading halts, as community discussion focuses on its extremely low float and high insider ownership for a potential short squeeze. Many are comparing it to recent explosive SPACs, with speculative targets suggesting significant upside, fueled by talking points like a rumored "sex toy manufacturer" acquisition. The stock's momentum reflects its position as a key play in the current "SPAC mania" for micro-float tickers.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is rapidly trending due to a potent combination of its extremely low share float and a potential short squeeze, driving significant momentum. The recent announcement of a strategic manufacturing partnership, expected to boost production margins, further amplifies investor interest. The community is actively discussing strong buying defense and a "textbook" short squeeze play as the company continues to expand global adoption of its fingerprint drug screening technology.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending amid renewed optimism driven by China's extension of EV trade-in subsidies into 2026 and robust Q4 sales forecasts, including potential record December deliveries. The community is actively discussing strong operational performance and strategic advancements like battery swapping, with many bullish investors accumulating shares on expectations of profitability. However, some continue to voice concerns over persistent market manipulation impacting the stock's valuation despite positive developments.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics (CORT) is trending due to the FDA issuing a Complete Response Letter for its relacorilant drug, triggering significant market volatility. The community is sharply divided, with some investors calling for further decline and celebrating put option gains, while others view the sell-off as an overreaction. Many highlight the company's existing profitable drug and argue that the FDA's acknowledgment of positive trial data suggests a path forward, creating a potential dip-buying opportunity.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals (VNDA) is trending following its recent FDA approval of NEREUS, the first new motion sickness treatment in over four decades, validating a significant pipeline asset. Community discussion highlights the drug's broader potential for GLP-1 induced nausea, fueling speculation of substantial upside, a potential short squeeze, and even a buyout, given the company's strong financial standing and additional upcoming regulatory catalysts.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings (ONDS) is trending due to recent autonomous system orders and the FCC's ban on foreign-made drones, which significantly boosts its role in the domestic market. The community is actively discussing a potential short squeeze and anticipating a significant price breakout, with many seeing dips as buying opportunities. This positions Ondas as a crucial player in the growing defense and critical infrastructure sectors for autonomous and counter-drone solutions.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after rival Corcept Therapeutics received an FDA Complete Response Letter for its Cushing's syndrome drug, effectively removing a near-term competitor for Xeris's Recorlev. The community is buzzing with bullish sentiment, emphasizing Recorlev's blockbuster potential and the significant undervaluation of XERS, further supported by advancing pipeline assets like XP-8121 and robust gross margins.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amidst a wave of strong bearish sentiment, largely attributed to sustained selling pressure, high short interest, and year-end tax loss harvesting. The community is actively discussing the recent FDA approval of Novo Nordisk's oral Wegovy pill, seeing a potential for partnership and a significant catalyst for HIMS's future growth in GLP-1 offerings, alongside its ongoing expansion in D2C lab testing and international markets. Despite current frustration, many long-term investors are using this dip as a buying opportunity, anticipating a strong reversal.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending following its CEO's strategic insights on CNBC and news of spinning off its cloud business into ChronoScale, a move seen by many as unlocking significant value and clarifying its pure-play AI data center infrastructure focus. The community is actively discussing sustained demand from hyperscalers and strong analyst confidence ahead of its upcoming earnings report, fueling bullish sentiment despite recent price volatility. This strategic realignment aims to capitalize on the booming AI infrastructure market with a clearer business model and substantial contracted revenue.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending due to the FDA's acceptance and priority review of its supplemental New Drug Application for AXS-05 in Alzheimer's disease agitation, with an action date anticipated in the near future. This significant regulatory milestone, combined with growing sales of its existing CNS therapies like Auvelity, has ignited immense optimism within the community, with many anticipating substantial long-term value and discussing breakthrough potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Abercrombie &amp; Fitch Co. (ANF) plummeted 15% on Wednesday, marking the company’s most significant intraday drop in over two years, despite the firm posting strong Q2 results that beat Wall Street expectations.Second-quarter revenue rose 21% year-over-year to $1.13 billion, surpassing analyst projections of $1.10 billion. Earnings per share (EPS) hit $2.50, also beating expectations of $2.22.Comparable sales grew by 18%, above the anticipated 15% growth, driven primarily by the performance of the Hollister chain, while sales at Abercrombie stores met estimates.Gross margin fell slightly short of expectations, and the company’s full-year outlook was largely in line with forecasts. For the current quarter, Abercrombie projects sales to grow by a low double-digit percentage.CEO Fran Horowitz, while noting the company’s strong first half, warned, “Although we continue to operate in an increasingly uncertain environment, we remain steadfast in executing our global playbook and maintaining discipline over inventory and expenses.”Adam Crisafulli, an analyst at Vital Knowledge, reportedly noted that Abercrombie is “held to a higher standard than most retailers” and said “people will probably be modestly underwhelmed” by the results.Last month, Argus Research downgraded ANF from ‘Buy’ to ‘Hold.’ While the firm acknowledged Abercrombie’s advantages from improved supply chains and growth in average unit retail, it projected that the company’s growth rate could moderate to mid-single digits by FY26.Argus also noted that Abercrombie shares trade at a “significant premium” in terms of price-to-sales and enterprise value-to-sales ratios relative to its peer group.ANF currently has a price-to-earnings (PE) ratio of 20.73, compared to Gap, Inc.’s (GPS) 12.97, even as they have similar market capitalizations.Despite the day’s dip, ANF stock remains up more than 52% for the year, outperforming its peers in the S&amp;P Composite 1500 Apparel Retail Index.On Stocktwits, retail investors showed little concern over the dip, with sentiment remaining ‘extremely bullish.’<figure class="image"><img style="aspect-ratio:1320/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ANF_sentiment_and_message_volume_Aug_28_933d435f51.png" alt="ANF sentiment and message volume Aug 28.png" width="1320" height="318"><figcaption>ANF sentiment and message volume Aug 28</figcaption></figure>Many saw the sell-off as an over-reaction, emphasizing Abercrombie’s strong earnings and guidance.<stembedurl>https://stocktwits.com/The_Titan_Traders/message/584368530</stembedurl>Others view the decline as a buying opportunity.<stembedurl>https://stocktwits.com/RoundAssRousey/message/584386905</stembedurl>The broader retail apparel sector has faced mixed earnings, with several companies citing macroeconomic headwinds and high inflation as factors making consumers more price-conscious.However, there might be some relief on the horizon. With the Federal Reserve expected to cut interest rates next month, there’s hope that consumer spending might bounce back and benefit retail stocks.Read Next: <a href="https://stocktwits.com/news/markets/equity/chewy-stock-rises-after-upbeat-q2-earnings/c7w7BeTR2T">Chewy Stock Rises 5% After Q2 Net Income Jumps 14x: Retail Goes Crazy</a>&nbsp;&nbsp; &nbsp;

Despite the day’s dip, ANF stock remains up more than 52% for the year.

Abercrombie & Fitch Stock Sinks As CEO Points To 'Increasingly Uncertain Environment' — Retail Bulls Aren’t Backing Down

Shares of Abercrombie & Fitch Co. (ANF) plummeted 15% on Wednesday, marking the company’s most significant intraday drop in over two years, despite the firm posting strong Q2 results that beat Wall Street expectations.

ANF Stocks Sinks As CEO Points To 'Increasingly Uncertain Environment

Equity

Despite strong Q2 results, including revenue growth of 21% and EPS surpassing expectations, the broader market appeared disappointed. But not retail investors.


XJR
iShares ESG Screened S&P Small-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Latest XJR News

XJRiShares ESG Screened S&P Small-Cap ETF